TEVA - Teva Pharmaceutical Industries Limited
NYSE
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Tel Aviv,
Israel
Type: Equity
TEVA price evolution
TEVA
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2258 | $2991 | $3226 | $2249 |
| Short term investments | ||||
| Net receivables | $3766 | $3456 | $3408 | $3385 |
| Inventory | $3927 | $3949 | $4021 | $4051 |
| Total current assets | $11632 | $12297 | $12485 | $11425 |
| Long term investments | ||||
| Property, plant & equipment | $5931 | $5982 | $6147 | $6028 |
| Goodwill & intangible assets | $21341 | $22063 | $22564 | $22410 |
| Total noncurrent assets | $29706 | $30476 | $30994 | $30663 |
| Total investments | ||||
| Total assets | $41338 | $42773 | $43479 | $42088 |
| Current liabilities | ||||
| Accounts payable | $2366 | $2439 | $2602 | $2280 |
| Deferred revenue | ||||
| Short long term debt | $2094 | $3060 | $1672 | $1479 |
| Total current liabilities | $13037 | $13792 | $12247 | $11394 |
| Long term debt | $16828 | $16878 | $18481 | $18819 |
| Total noncurrent liabilities | $21737 | $21438 | $23106 | $23182 |
| Total debt | $18922 | $19938 | $20153 | $20298 |
| Total liabilities | $34774 | $35230 | $35353 | $34576 |
| Shareholders' equity | ||||
| Retained earnings | -$14519 | -$13673 | -$13534 | -$13870 |
| Other shareholder equity | -$2881 | -$2775 | -$2697 | -$2910 |
| Total shareholder equity | $6359 | $7278 | $7506 | $6930 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $3226 | $2801 | $2165 | $2177 |
| Short term investments | ||||
| Net receivables | $3408 | $3696 | $4529 | $4581 |
| Inventory | $4021 | $3833 | $3818 | $4403 |
| Total current assets | $12485 | $12051 | $12573 | $13005 |
| Long term investments | ||||
| Property, plant & equipment | $6147 | $6158 | $6477 | $6855 |
| Goodwill & intangible assets | $22564 | $23903 | $27506 | $29547 |
| Total noncurrent assets | $30994 | $31955 | $35093 | $37635 |
| Total investments | ||||
| Total assets | $43479 | $44006 | $47666 | $50640 |
| Current liabilities | ||||
| Accounts payable | $2602 | $1887 | $1686 | $1756 |
| Deferred revenue | ||||
| Short long term debt | $1672 | $2109 | $1426 | $3188 |
| Total current liabilities | $12247 | $11469 | $11027 | $13164 |
| Long term debt | $18481 | $19103 | $22033 | $23210 |
| Total noncurrent liabilities | $23106 | $23846 | $25395 | $26415 |
| Total debt | $20153 | $21561 | $23459 | $26398 |
| Total liabilities | $35353 | $36109 | $36422 | $39579 |
| Shareholders' equity | ||||
| Retained earnings | -$13534 | -$12882 | -$10529 | -$10946 |
| Other shareholder equity | -$2697 | -$2838 | -$2683 | -$2399 |
| Total shareholder equity | $7506 | $7897 | $10278 | $10026 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4164 | $3819 | ||
| Cost of revenue | $2140 | $2048 | ||
| Gross Profit | $2024 | $1771 | ||
| Operating activities | ||||
| Research & development | $269 | $242 | ||
| Selling, general & administrative | $939 | $886 | ||
| Total operating expenses | $2030 | $1987 | ||
| Operating income | -$6 | -$216 | ||
| Income from continuing operations | ||||
| EBIT | $25 | $59 | ||
| Income tax expense | $630 | -$52 | ||
| Interest expense | $241 | $250 | ||
| Net income | ||||
| Net income | -$846 | -$139 | ||
| Income (for common shares) | -$846 | -$139 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $15846 | $14925 | $15878 | $16659 |
| Cost of revenue | $8200 | $7952 | $8284 | $8933 |
| Gross Profit | $7646 | $6973 | $7594 | $7726 |
| Operating activities | ||||
| Research & development | $953 | $838 | $967 | $997 |
| Selling, general & administrative | $3498 | $3445 | $3528 | $3671 |
| Total operating expenses | $7213 | $9179 | $5977 | $11337 |
| Operating income | $433 | -$2206 | $1617 | -$3611 |
| Income from continuing operations | ||||
| EBIT | $491 | -$2025 | $1686 | -$3324 |
| Income tax expense | -$7 | -$638 | $211 | -$168 |
| Interest expense | $1057 | $966 | $1058 | $834 |
| Net income | ||||
| Net income | -$559 | -$2353 | $417 | -$3990 |
| Income (for common shares) | -$559 | -$2353 | $417 | -$3990 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$846 | -$139 | $429 | $80 |
| Operating activities | ||||
| Depreciation | $259 | $272 | $266 | $283 |
| Business acquisitions & disposals | $1 | -$15 | $10 | |
| Stock-based compensation | $32 | $28 | $28 | $31 |
| Total cash flows from operations | $103 | -$124 | $1184 | $5 |
| Investing activities | ||||
| Capital expenditures | -$97 | -$124 | -$119 | -$149 |
| Investments | $274 | $283 | $419 | $324 |
| Total cash flows from investing | $178 | $144 | $301 | $184 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$956 | -$500 | -$500 | |
| Total cash flows from financing | -$966 | -$151 | -$576 | -$576 |
| Effect of exchange rate | -$49 | -$104 | $68 | -$33 |
| Change in cash and equivalents | -$733 | -$236 | $977 | -$420 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$559 | -$2353 | $417 | -$3990 |
| Operating activities | ||||
| Depreciation | $1153 | $1308 | $1330 | $1557 |
| Business acquisitions & disposals | $68 | $61 | $311 | |
| Stock-based compensation | $121 | $124 | $119 | $129 |
| Total cash flows from operations | $1368 | $1590 | $798 | $1216 |
| Investing activities | ||||
| Capital expenditures | -$526 | -$548 | -$562 | -$578 |
| Investments | $1431 | $1143 | $1773 | $1350 |
| Total cash flows from investing | $968 | $656 | $1523 | $863 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$1701 | -$1369 | -$2166 | -$1880 |
| Total cash flows from financing | -$1913 | -$1487 | -$2172 | -$1885 |
| Effect of exchange rate | -$30 | -$123 | -$128 | $8 |
| Change in cash and equivalents | $393 | $636 | $21 | $202 |
News
Fundamentals
| Market cap | $18.96B |
|---|---|
| Enterprise value | $35.62B |
| Shares outstanding | 1.13B |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 2.05 |
| Book/Share | 8.16 |
| Cash/Share | 1.99 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 4.71 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.89 |
| Quick ratio | 0.59 |